Table 1.
Summary of physiologic data for A.C. over the 24‐month treatment period
| Outcome | Baseline | 3‐Month | 6‐Month | 9‐Month | 12‐Month | 18‐Month | 24‐Month | Change (raw, %) |
|---|---|---|---|---|---|---|---|---|
| MIP (cmH20) | 71 | 129 | 125 | 113 | 140 | 133 | 134 | +63 (+88.7%) |
| MEP (cmH20) | 108 | 144 | 139 | 148 | 186 | 186 | 197 | +89 (+82.4%) |
| FVC (%Predicted) | 104% | 102% | 112% | 109% | 114% | 101% | 104% | 0% (±0%) |
| PEF (L/min) | 331 | 618 | 570 | 474 | 544 | 642 | 655 | +324 (+97.8%) |
|
ALSFRS‐R ALSFRS‐R (b) ALSFRS‐R (r) |
46 10 12 |
45 10 12 |
44 9 12 |
44 9 12 |
−2 (−4.35%) −1 (−10%) 0 (±0%) |
MEP, maximum expiratory pressure; MIP, maximum inspiratory pressure; FVC, forced vital capacity; PEF, peak expiratory flow; ALSFRS‐R, amyotrophic lateral sclerosis functional rating scale revised total score; ALSFRS‐R (b), amyotrophic lateral sclerosis functional rating scale revised bulbar subscale score; ALSFRS‐R (r), amyotrophic functional rating scale revised respiratory subscale score.